Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-650 in Refractory Hodgkin's Lymphoma
NCT00441818Phase 2Unknown
- Sponsor
- Tanox, Inc.
- Start
- May 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lebrikizumab in Hodgkin lymphoma (HL), sponsored by Tanox, Inc.. Status: unknown.
02
Drugs
lebrikizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00441818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00441818.